文献
J-GLOBAL ID:201702233243505817
整理番号:17A1191672
2型糖尿病(SUSTAIN 2)と追加メトホルミン,チアゾリジンジオン,またはその両方の患者における週1回semaglutide対1日1回のシタグリプチンの有効性と安全性:56週間二重盲検相3a,無作為化試験【Powered by NICT】
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
著者 (7件):
Ahren Bo
(Department of Clinical Sciences, Division of Medicine, Lund University, Lund, Sweden)
,
Masmiquel Luis
(Balearic Institute of Endocrinology and Nutrition (IBEN), Hospital Quironsalud Palmaplanas, Palma de Mallorca, Spain)
,
Kumar Harish
(Amrita Viswa Vidyapeetham University, Kochi, Kerala, India)
,
Sargin Mehmet
(Kartal Training and Research Hospital, Istanbul, Turkey)
,
Karsbol Julie Derving
(Novo Nordisk A/S, Soborg, Denmark)
,
Jacobsen Sanja Hald
(Novo Nordisk A/S, Soborg, Denmark)
,
Chow Francis
(Chinese University of Hong Kong, Hong Kong, China)
資料名:
Lancet Diabetes & Endocrinology
(Lancet Diabetes & Endocrinology)
巻:
5
号:
5
ページ:
341-354
発行年:
2017年
JST資料番号:
W3110A
ISSN:
2213-8587
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)